Gene and protein therapies utilizing VEGF for ALS.
Pharmacol Ther
; 141(3): 261-71, 2014 Mar.
Article
en En
| MEDLINE
| ID: mdl-24177067
Palabras clave
AAV; ALS; CNS; Clinical trials; FIG4; FTD; FUS; Gene therapy; HRE; ICV; IGF-1; NFκB; NRP; PlGF; Protein therapy; SETX; SOD1; TAR DNA-binding domain protein; TDP43; UBQLN2; UTR; VEGF; VEGFR; adeno-associated virus; amyotrophic lateral sclerosis; central nervous system; frontotemporal dementia; fused in sarcoma; hypoxia response element; insulin-like growth factor 1; intracerebroventricular; neuropilin; nuclear factor kappa-light-chain-enhancer of activated B cells; placental growth factor; polyphosphoinositide phosphatase; senataxin; superoxide dismutase 1; ubiquitin-like protein ubiquilin 2; untranslated region; vascular endothelia growth factor receptor; vascular endothelial growth factor
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Terapia Genética
/
Factor A de Crecimiento Endotelial Vascular
/
Esclerosis Amiotrófica Lateral
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Pharmacol Ther
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos